Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS (TYNERGY)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00884481|
Recruitment Status : Completed
First Posted : April 20, 2009
Last Update Posted : July 13, 2015
|Condition or disease||Intervention/treatment|
|Relapsing-Remitting Multiple Sclerosis Fatigue||Other: Natalizumab|
|Study Type :||Observational|
|Actual Enrollment :||200 participants|
|Official Title:||A Multi-centre and Prospective Trial to Evaluate the Effects on Multiple Sclerosis Related Fatigue During Treatment With Tysabri in Patients With Relapsing Remitting Multiple Sclerosis Over the Course of 12 Months|
|Study Start Date :||March 2009|
|Primary Completion Date :||June 2011|
|Study Completion Date :||June 2011|
Participants with MS treated with Tysabri over 12 months
Participants treated with Tysabri
- To investigate the MS related fatigue during treatment with Tysabri as measured by changes in the fatigue scale for motor and cognitive functions (FMSC) over the course of 12 months. [ Time Frame: 0 month and 12 months ]A fatigue scale for motor and cognitive functions (FSMC) has been developed and validated by Penner et al. FSMC differentiates between motor and cognitive fatigue and is less susceptible to confounding by depression. Thus, FSMC is more specific in measuring MS-related fatigue.
- Changes in fatigue after initiation of Tysabri treatment [ Time Frame: 3 months, 6 months, 9 months ]
- Change in capacity for work (capacity for work questionnaire (CWQ)) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ]Capacity for Work Questionnaire (CWQ) is used to collect data regarding number of working hours and sickness absence.
- Change in health-related-quality of life (HRQ0L) (short form-12 questions (SF-12)) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ]The SF-12 is a multipurpose short form survey with 12 questions, all selected from the SF-36 Health Survey. The questions were combined, scored, and weighted to create two scales that provide glimpses into mental and physical functioning and overall HRQOL. Physical and Mental Health Composite Scores (PCS & MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health and 100 indicates the highest level of health.
- Change in Sleepiness (Epworth sleepiness scale (ESS)) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ]The ESS is a self-administered 8-item questionnaire with that provides a measure of a person's general level of daytime sleepiness, or their average sleep propensity in daily life. Each question is rated on a 4-point scale (0 - 3), their usual chances of dozing off or falling asleep in 8 different situations or activities that most people engage in as part of their daily lives, although not necessarily every day. The total ESS score is the sum of 8 item-scores and can range between 0 and 24, where higher scores indicate higher levels of a person's level of daytime sleepiness.
- Change in cognitive impairment (the paced auditory serial addition test (PASAT) and symbol digit modalities test (SDMT)) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ]The PASAT is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability. Single digits are presented every 3 seconds and the patient must add each new digit to the one immediately prior to it. The PASAT is the third and last component of the MSFC. SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best).
- Change in depression (Center for epidemiologic studies depression scale (CES-D)) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ]CES-D is a self-report measure of depression severity.
- Change in Physical activity induced exhaustion (Borg scale CR10 (BS-CR10)) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ]The Borg Scale measures perceived exertion. It is used to document the patient's exertion during a test. It ranges from 6 to 20, where 6 means "no exertion at all" and 20 means "maximal exertion.
- Change in speed of walking (6MWT) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ]The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.
- Change in status of MS disease progression (expanded disability status scale (EDSS)) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ]The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist.
- Change in amount of walking (step counter) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ]
- To investigate correlation between fatigue and cognitive impairment, depression and physically activity induced exhaustion and status of MS disease progression [ Time Frame: 6 months, 12 months ]
- To document any changes in fatigue related medication [ Time Frame: 12 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00884481
|United States, Illinois|
|University of Chicago|
|Chicago, Illinois, United States, 60637|
|Study Director:||Medical Director||Biogen|